Main Menu Jump to Page






The Rosen Law Firm Announces Investigation of Securities ClaimsAgainst Chemed Corporation – CHE

New York, N.Y., May 21, 2013.  The Rosen Law Firm announces that it is investigating potential securities claims against Chemed Corporation (the "Company") (NYSE: CHE) resulting from allegations that Chemed’s Vitas hospice business knowingly overbilled the Medicare program. 

Vitas is the largest for-profit hospice care chain in the United States.  It was acquired by Chemed in 2004.  On May 2, 2013, the United States Department of Justice (“DOJ”) filed a lawsuit against Chemed and its affiliates alleging the Company violated the False Claims Act by systematically defrauding Medicare.  Specifically, the DOJ’s complaint alleges that Chemed knowingly submitted or caused the submission of false Medicare claims for hospice services that were unnecessary, were not provided, or were provided to patients who were ineligible under Medicare requirements.  As a result of this news, Chemed shares fell over 15%.

The Rosen Law Firm is investigating a securities class action lawsuit on behalf of Chemed investors.  If you purchased Chemed stock before May 2, 2013, please visit the website at for more information.  You may also contact Jonathan Horne, Esq., or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at or

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising.  Prior results do not guarantee a similar outcome.